Trials success for ambitious Arecor
Arecor’s ultra-concentrated ultra-rapid acting insulin, AT278, met all its primary and secondary endpoints with positive headline results from a Phase I clinical trial, the Cambridge company has reported.
AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume.
Currently, there are no concentrated (>200 U/mL) rapid acting insulin products on the market so AT278 has the potential to be the first such product available to patients.
It is tipped to enable more effective management of blood glucose levels to the increasing number of people with diabetes with high daily insulin requirements (>200 units/day) whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection.
A truly rapid acting concentrated insulin is also a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices.
Sarah Howell, Arecor’s CEO, said: “The successful completion of our AT278 Phase I clinical trial is an important milestone for Arecor. AT278 has the potential to disrupt the market for insulin treatment in people with diabetes, as the first concentrated, yet rapid acting, insulin – a critical enabler in the development of next generation miniaturised insulin delivery systems.
“The study had been designed to achieve PK/PD equivalence with a comparable dose of lower concentration NovoRapid®. The achievement of a superior PK/PD profile goes beyond our expectations.
“These positive data for AT278, the second product in our diabetes franchise, follow the earlier positive results from the Phase I clinical trial of AT247, our ultra-rapid acting insulin for diabetes.
“Together they position Arecor with a unique combination of ultra-concentrated and ultra-rapid insulin candidates offering the potential to meet the broad needs of patients across the growing diabetes market.”
The next step will be further clinical investigation of the potential benefits of the ultra-rapid acting profile of AT278 to further optimise the positive results obtained in this first clinical study.
Detailed data from the trial will be submitted for presentation at a future international diabetes conference.